Skip to content

Otsuka#39;s drug for Alzheimer#39;s disease agitation fails in late stage study

The treatment, AVP-786, failed to achieve statistically significant difference on the primary trial goal testing the efficacy of the candidates, compared to placebo.

Read More

​ The treatment, AVP-786, failed to achieve statistically significant difference on the primary trial goal testing the efficacy of the candidates, compared to placebo. The treatment, AVP-786, failed to achieve statistically significant difference on the primary trial goal testing the efficacy of the candidates, compared to placebo.  Moneycontrol Latest News Read More  

Leave a Reply

en_USEnglish